Literature DB >> 3531031

A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues.

H H Hagemeier, E Vollmer, S Goerdt, K Schulze-Osthoff, C Sorg.   

Abstract

This report describes a monoclonal antibody (MAb) generated by immunization of mice with cell suspensions of capillary-rich fragments of mammary carcinomas. The antibody (EN 7/44) belongs to the IgM class and detects a 30.5 kDa antigen which is found in the cytoplasm of human placental and umbilical vein-endothelial cells (HUVEC) and on the surface of tumor endothelium. Using indirect immunofluorescence and immunoperoxidase techniques, we did not find the MAb in peripheral blood cells or in any human cell lines tested, nor in endothelial cells from normal, nonproliferating adult tissues. Positively staining endothelium was found in the placenta, the umbilical vein and in proliferating normal tissues (intestine). Positive endothelial cells were found in acute inflammatory reactions and in tumors. In the latter, the strongest reactions were seen in newly formed budding capillaries, which were identified by their reactivity with Ulex europaeus I-lectin and antibodies against F VIII-RAG. In tumor tissues, large vessels could be positively stained with the EN 7/44 antigen, in contrast to inflammatory tissues. It is concluded that endothelial cells at the tip of a budding capillary express distinct phenotypic characteristics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531031     DOI: 10.1002/ijc.2910380405

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Targeting and imaging signature caveolar molecules in lungs.

Authors:  Kerri A Massey; Jan E Schnitzer
Journal:  Proc Am Thorac Soc       Date:  2009-08-15

Review 2.  Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy.

Authors:  G Molema; L F de Leij; D K Meijer
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

Review 3.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds.

Authors:  R O Schlingemann; F J Rietveld; R M de Waal; S Ferrone; D J Ruiter
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

5.  In situ detection of basic fibroblast growth factor by highly specific antibodies.

Authors:  K Schulze-Osthoff; W Risau; E Vollmer; C Sorg
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

6.  Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue.

Authors:  R O Schlingemann; F J Rietveld; F Kwaspen; P C van de Kerkhof; R M de Waal; D J Ruiter
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

7.  Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression.

Authors:  H G Augustin; K Braun; I Telemenakis; U Modlich; W Kuhn
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

Review 8.  Vascular attack as a therapeutic strategy for cancer.

Authors:  J Denekamp
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

Review 9.  Antibody-directed targeting of the vasculature of solid tumors.

Authors:  P E Thorpe; F J Burrows
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  Expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on proliferating vascular endothelial cells in diabetic epiretinal membranes.

Authors:  S Tang; K C Le-Ruppert; V P Gabel
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.